Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 512529 | NSE Symbol : SEQUENT | ISIN : INE807F01027 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
04-Feb-2025	11-Feb-2025	Quarterly Results	SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 inter alia to consider and approve Meeting of the Board of Directors of SeQuent Scientific Limited is scheduled to be held on Tuesday February 11 2025 to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2024 Pursuant to Regulation 30 and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors at its Meeting held today i.e., February 11, 2025, upon the recommendation of the Audit Committee, has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024 (As Per BSE Announcement Dated on: 11/02/2025)
06-Nov-2024	13-Nov-2024	Quarterly Results	SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of SeQuent Scientific Limited is scheduled to be held on Wednesday November 13 2024 to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended September 30 2024. Q2FY25 Results (As per BSE Announcement Dated on 13/11/2024)
26-Sep-2024	26-Sep-2024	Others	We wish to inform you that Board of Directors of the Company, at their meeting held today (i.e. September 26, 2024)
09-Aug-2024	14-Aug-2024	Quarterly Results	SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of SeQuent Scientific Limited is scheduled to be held on Wednesday August 14 2024 to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30 2024. Sequent Result Q1 FY 2024-25 (As Per Bse Announcement Dated on 14.08.2024)
08-May-2024	15-May-2024	Final Dividend	SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2024 inter alia to consider and approve Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of SeQuent Scientific Limited is scheduled to be held on Wednesday May 15 2024 inter alia to: 1. Consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2024. 2. Consider dividend for the year ended March 31 2024 if any. Audited standalone and Consolidated Financial Results for the quarter and Year ended March 31, 2024. The Board has not recommended any dividend for F.Y. 2023-24. Audited standalone and Consolidated Financial Results for the quarter and Year ended March 31, 2024 1. Audited Consolidated Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2024 with an unmodified opinion. 2. Audited Standalone Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2024 with an unmodified opinion. 3. The Board has not recommended any dividend for F.Y. 2023-24. (As Per BSE Announcement Dated on: 15/05/2024)
06-Feb-2024	13-Feb-2024	Quarterly Results	SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2023. Financial results for quarter ended December 31 2023 Appointment of Company Secretary and Compliance Officer (As Per BSE Announcement dated on 13.02.2024)
05-Feb-2024	05-Feb-2024	Postal Ballot	Pursuant to Regulation 30 (read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the following: 1. Notice of Postal Ballot for seeking Members approval, a) To create security on the undertakings of the Company under Section 180(1)(a) of the Companies Act, 2013 and, b) To consider and approve the divestment by the Company of its shareholding and beneficial interest in material subsidiary of the Company and to approve sale, disposal, and lease of assets exceeding 20% of the assets of the material subsidiaries of the Company pursuant to the provisions of Regulation 24(5) & 24(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Re-submission of outcome dated February 05, 2024 (As Per BSE Announcement Dated on 22/05/2024)
30-Oct-2023	06-Nov-2023	Quarterly Results	SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2023 inter alia to consider and approve Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of SeQuent Scientific Limited is scheduled to be held on Monday November 06 2023 to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended September 30 2023. Disclosure of unaudited consolidated and standalone financial results for quarter and half year ended September 30, 2023 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2023. In this regard, kindly find enclosed the following: 1. Unaudited Consolidated Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and half year ended September 30, 2023. 2. Unaudited Standalone Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and half year ended September 30, 2023. The Board Meeting commenced at 08:15 p.m. and concluded at 09:55 p.m. Appointment of Mr. Saurav Bhala as Chief Financial Officer of the Company (As Per BSE Announcement Dated on 06.11.2023)
14-Sep-2023	14-Sep-2023	Change in Auditors	Pursuant to Regulation 30 (read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the following: 1. Sale/Transfer of the Company's API facility situated at Tarapur, Boisar Dist. Thane, Maharashtra - 401506, India. Disclosure as required under Regulation 30 of SEBI LODR read with Schedule III, Part A, A.1 will be provided when a binding agreement is entered into for the proposed sale. 2. Appointment of M/s. Grant Thornton Bharat LLP, Chartered Accountants as Internal Auditors of the Company.3. Notice of Postal Ballot for seeking Members approval for Sale/Transfer of the Company's API facility situated at Tarapur, Boisar Dist. Thane, Maharashtra - 401506, India. Outcome of Board Meeting held on September 14, 2023
04-Aug-2023	10-Aug-2023	Quarterly Results	SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 inter alia to consider and approve Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of SeQuent Scientific Limited is scheduled to be held on Thursday August 10 2023 to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30 2023. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2023. In this regard, kindly find enclosed the following: 1. Unaudited Consolidated Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter ended June 30, 2023. 2. Unaudited Standalone Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter ended June 30, 2023. The Board Meeting commenced at 08:15 p.m. and concluded at 10:00 p.m. (As per BSE Announcement Dated on 10/08/2023)
16-May-2023	23-May-2023	Accounts	SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2023 inter alia to consider and approve 1. the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2023. 2. dividend for the year ended March 31 2023 if any. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2023. In this regard, kindly find enclosed the following: 1. Audited Consolidated Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2023 with an unmodified opinion. 2. Audited Standalone Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2023 with an unmodified opinion. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2023. In this regard, kindly find enclosed the following: 1. Audited Consolidated Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2023 with an unmodified opinion. 2. Audited Standalone Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2023 with an unmodified opinion. 3. The Board has not recommended any dividend for F.Y. 2022-23. (As Per BSE Announcement Dated on 23/05/2023) Equity NIL Dividend (As Per BSE Bulletin Dated on 24.05.2023)
08-Feb-2023	14-Feb-2023	Quarterly Results	SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2022. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors at its Meeting held today i.e. February 14, 2023, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2022. The Board of Directors at its meeting held today, viz. February 14, 2023, has considered and approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2022. A copy of the said results along with the limited review report and , is enclosed. A press release along with the investor presentation issued in this regard, is also enclosed. The Board of Directors at its meeting held today, viz. February 14, 2023, has considered and approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2022. A copy of the said results along with the limited review report and , is enclosed. A press release along with the investor presentation issued in this regard, is also enclosed. (As Per BSE Announcement Dated on 14.02.2023)
02-Nov-2022	07-Nov-2022	Quarterly Results	SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2022 inter alia to consider and approve Further to our intimation dated November 1 2022 regarding the Board Meeting of the Company scheduled for November 7 2022 to consider and approve the un- audited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30 2022 we wish to inform you that the Board will also evaluate a proposal for the issuance of equity shares through preferential issue to Persons other than Promoters in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018 and the Companies Act 2013 as amended. SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2022 ,inter alia, to consider and approve The Meeting of the Board of Directors of SeQuent Scientific Limited is scheduled to be held on Monday, November 07, 2022, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2022. (As Per BSE Announcement Dated on 01.11.2022) Sequent Scientific Limited has informed the Exchange that the Board of Directors of the Company at their meeting held today, have inter alia considered and approved the following: 1. Acquisition of entire 100% stake in Tineta Pharma Private Limited ('Tineta') 2. Issuance of equity shares of face value Rs. 2/- each fully paid up of the Company for a value of Rs. 65,00,00,000/- (Rupees Sixty-Five Crores only), at a price not lower than the floor price 3. Amendment to 'SeQuent Scientific Limited Employees Stock Option Plan, 2020' (ESOP Scheme), subject to approval of the shareholders. 4. Postal Ballot notice. Sequent Scientific Limited has informed the Exchange that the Board of Directors of the Company at their meeting held today, have inter alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2022. Sequent Scientific Limited has informed the Exchange that the Board of Directors of the Company at their meeting held today, have inter alia considered and approved the following: 1. Acquisition of entire 100% stake in Tineta Pharma Private Limited ('Tineta') 2. Issuance of equity shares of face value Rs. 2/- each fully paid up of the Company for a value of Rs. 65,00,00,000/- (Rupees Sixty-Five Crores only), at a price not lower than the floor price 3. Amendment to 'SeQuent Scientific Limited Employees Stock Option Plan, 2020' (ESOP Scheme), subject to approval of the shareholders. 4. Postal Ballot notice. (As Per BSE Announcement Dated on 07.11.2022)
01-Aug-2022	08-Aug-2022	Quarterly Results	SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2022 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30 2022. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2022. (As Per BSE Announcement Dated on 08/08/2022) The Board of Directors at their meeting held on August 08, 2022, has re-constituted the 'Materiality Committee' of the Company with effect from August 08, 2022. (As Per BSE Announcement Dated on 09.08.2022)
18-May-2022	25-May-2022	Accounts	SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2022 inter alia to consider and approve Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of SeQuent Scientific Limited (the Company) is scheduled to be held on Wednesday May 25 2022 to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2022. Further in continuation to our intimation dated March 31 2022 and pursuant to Companys Code of Conduct to Regulate Monitor and Report Trading by Designated Persons and their Immediate Relatives the trading window for dealing in the securities of the Company is closed from April 01 2022 till 48 hours after the declaration of Audited Financial Results of the Company for the quarter and year ended March 31 2022. Kindly take the above on records. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2022. In this regard, kindly find enclosed the following: 1. Audited Consolidated Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2022. 2. Audited Standalone Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2022. 3. A copy of Press Release and Investors Presentation on Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2022. (As Per BSE Announcement Dated on 25.05.2022) We wish to inform you that the Board of Directors at their meeting held on May 25, 2022 has constituted a committee named 'Materiality Committee' to determine materiality of an event or information for the purpose of making disclosures to the Stock Exchanges. (As Per BSE Announcement Dated on 26/05/2022)

1 2

LOGIN HERE

Sequent Scientific Ltd

Board Meeting